Two potential tumor antigens, ZNF831 and SYNE1, showed significant superior prognostic effects and positive correlations with antigen presenting cells, which provided promising candidates for the development of tumor antigen‐based mRNA vaccine. Here, SYNE1 is linked to neoplasm.